Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05179512 · ClinicalTrials.gov registry record
Replication of the INSPIRE Trial in Healthcare Claims Data
A clinical trial of Chronic Obstructive Pulmonary Disease, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 98,278
- Enrollment target
- 1
- Study location
NCT05179512: Completed study of Chronic Obstructive Pulmonary Disease, sponsored by Brigham and Women's Hospital.
NCT05179512 is a study of Chronic Obstructive Pulmonary Disease that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 98,278 participants, above the 611-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (15985% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05179512, a study of Chronic Obstructive Pulmonary Disease, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 98,278 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Primary Outcome
Claims-based algorithm: healthcare utilization exacerbation rate per year
Conditions Studied
Interventions
- DRUG Tiotropium
- DRUG salmeterol-fluticasone
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98,278 participants |
| Start Date | 2020-09-22 |
| Est. Completion | 2021-08-30 |
What the finished NCT05179512 record still lists
NCT05179512 is an observational study that tracks outcomes without assigning an intervention. Its 98,278 participants enrollment target places it among the larger protocols in the corpus, above the 611-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (15985% higher).
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 2 interventions - of which Tiotropium is the first listed.
NCT05179512 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05179512 about?
NCT05179512 is a clinical study titled "Replication of the INSPIRE Trial in Healthcare Claims Data". Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such...
What is the current status of trial NCT05179512?
This trial is currently completed. The enrollment target is 98,278 participants. The study started on 2020-09-22. Estimated completion is 2021-08-30.
What conditions does trial NCT05179512 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT05179512?
The interventions under investigation include: Tiotropium (DRUG), salmeterol-fluticasone (DRUG).
Who is sponsoring clinical trial NCT05179512?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05179512 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05179512's enrollment target sits among peer trials
98,278 1st of 86 higher than 86 of 86 other Chronic Obstructive Pulmonary Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mindful Steps 2.0: Promoting Physical Activity in Patients With COPD and HF
RECRUITING · NA
-
Boston Early-Onset Chronic Obstructive Pulmonary Disease (COPD) Study
RECRUITING
-
Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
RECRUITING · NA
-
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
RECRUITING · Phase 2
-
The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)
RECRUITING · Phase 2
-
COPD Care Pathway Among Patients With Cancer
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01351545 · 99,999 participants
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- NCT02620852 · 100,000 participants · NA
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- NCT03277365 · 100,000 participants · NA
MyGeneRank: A Digital Platform for Next-Generation Genetic Studies
- NCT04281823 · 100,000 participants
DeBakey Cardiovascular Magnetic Resonance Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI